Date: 2011-07-12
Type of information: R&D agreement
Compound:
Company: Ipsen (France) Institut Gustave Roussy - IGR (France)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: Ipsen and Institut de cancérologie Gustave Roussy (IGR, Villejuif) have announced the signature of a partnership in the area of medical oncology to leverage the combined expertises of their respective R&D teams. This 3 year agreement was signed on 27 June 2011. Facing the complexity of the current challenges of cancer treatment, the common commitment of Institut Gustave Roussy and Ipsen through their partnership will result in:
- The identification of innovative therapeutic targets involved in the development process of cancers,
- The optimization of joined new therapeutic and biomarker programmes so as to accelerate the transition between preclinical development towards clinical proof of concept studies,
- Eventually, the design and implementation of the most relevant clinical studies for patient care.
In the current development paradigm of personalized treatments for cancers, this collaboration between Institut Gustave Roussy and Ipsen will be beneficial in contributing, for certain cancers, especially in uro-oncology, to a more accurate understanding of the dysregulated biological pathways which favour their progression. Beyond its interest for the selection of therapeutic targets, this partnership will enable Ipsen and Institut Gustave Roussy to cross-fertilize their medical and scientific experiences, in particular in the area of early therapeutic development.
Financial terms:
Latest news:
